Core Viewpoint - Enwei Pharmaceutical (301331) will disclose shareholder information in its periodic reports, and investors are advised to pay attention to the company's announcements in designated information disclosure media [1] Group 1 - The company confirmed that shareholder account information will be included in its regular reports [1] - Investors are encouraged to monitor the company's disclosures through specified channels [1]

重要内容提示： 一、本次询价转让初步定价 证券代码：301331 证券简称：恩威医药 公告编号：2026-003 恩威医药股份有限公司 股东询价转让定价情况提示性公告 股东成都恩威投资（集团）有限公司保证向恩威医药股份有限公司提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 （一）经向机构投资者询价后，初步确定的转让价格为26.54元/股。 （二）参与本次询价转让报价的机构投资者家数为30家，涵盖了基金管理公 司、证券公司、保险公司、私募基金管理人、合格境外投资者等专业机构投资者。 参与本次询价转让报价的机构投资者合计有效认购股份数量为16,476,000股，对 应的有效认购倍数为4.12倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为11名机构 投资者，拟受让股份总数为4,000,000股。 二、相关风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股份被 司法冻结、扣划等风险。询价转让的最终结果以中国证券登记结算有限责任公司 1 根据2026年 ...

Core Viewpoint - Enwei Pharmaceutical (301331.SZ) announced a share transfer plan involving its major shareholder, Chengdu Enwei Investment (Group) Co., Ltd., which intends to transfer 4,000,000 shares, representing 3.89% of the total share capital [1] Group 1: Share Transfer Details - The total share capital of Enwei Pharmaceutical is 102,891,887 shares, with 1,055,326 shares held in a repurchase account [1] - The proposed transfer will not occur through centralized bidding or block trading, and the transferee will be institutional investors with appropriate pricing and risk-bearing capabilities [1] - The shares transferred will be restricted from being sold for six months after the transfer [1] Group 2: Shareholder Information - Chengdu Enwei Investment (Group) Co., Ltd. holds 13.45% of the company's shares after the transfer [2] - Based on the closing price of 30.51 yuan per share, the cash amount from this transfer is approximately 122 million yuan [2] - As of the announcement date, Chengdu Enwei Investment (Group) Co., Ltd. and its concerted parties have pledged 50,420,836 shares, accounting for 70.91% of their holdings and 49.00% of the total share capital [2]

Group 1 - The core point of the article is that Enwei Pharmaceutical (301331.SZ) is planning to participate in the pre-IPO share transfer, with Chengdu Enwei Investment (Group) Co., Ltd. as the selling shareholder [1] - The total share capital of the company is 102,891,887 shares, with 1,055,326 shares held in the company's repurchase special securities account [1] - The selling shareholder intends to transfer a total of 4,000,000 shares, which represents 3.89% of the company's total share capital and 3.93% of the total share capital excluding the repurchased shares [1]

Core Viewpoint - Enwei Pharmaceutical (301331.SZ) announced that its controlling shareholder, Chengdu Enwei Investment (Group) Co., Ltd., plans to transfer 4 million shares through a pricing inquiry, representing 3.89% of the company's total share capital and 3.93% of the total share capital after excluding repurchased shares. The reason for the transfer is due to the shareholder's funding needs. The transfer will not be conducted through centralized bidding or block trading, and the shares acquired through the inquiry transfer cannot be transferred by the acquirer within six months [1]. Group 1 - The controlling shareholder plans to transfer 4 million shares [1] - The shares represent 3.89% of the total share capital [1] - The transfer is motivated by the shareholder's funding needs [1] Group 2 - The transfer will not occur through centralized bidding or block trading [1] - Acquired shares cannot be transferred within six months [1]

中信证券股份有限公司 关于恩威医药股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 中信证券股份有限公司（以下简称"中信证券"）受恩威医药股份有限公司 （以下简称"恩威医药"）股东成都恩威投资（集团）有限公司（以下简称"出 让方"）委托，组织实施本次恩威医药首发前股东向特定机构投资者询价转让（以 下简称"本次询价转让"）。 中信证券核查了成都恩威投资（集团）有限公司提供的工商登记文件并对企 1、成都恩威投资（集团）有限公司 | 企业名称 | 成都恩威投资（集团）有限公司 915101007160263882 | 统一社会信用代码 | | | --- | --- | --- | --- | | 类型 | 有限责任公司 1995 年 7 1 日 | 成立日期 | 月 | | 注册地址 | 成都市高新区创业路 号 28 | | | | 经营范围 | 项目投资（不得从事非法集资、吸收公众资金等金融活动），技术咨询服务； | | | | | 销售日用百货、五金交电、化工产品（不含危险品）。进出口贸易（法律法规 | | | | | 限制或禁 ...

证券代码：301331 证券简称：恩威医药 公告编号：2026-002 恩威医药股份有限公司 股东询价转让计划书 股东成都恩威投资（集团）有限公司保证向恩威医药股份有限公司提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对真实性、准确性和 完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次拟参与恩威医药股份有限公司（以下简称"公司"）首次公开发行前 （以下简称"首发前"）股东询价转让的股东为成都恩威投资（集团）有限公司（以 下简称"出让方"）； 公司总股本为102,891,887股，其中公司回购专用证券账户持有1,055,326 股。本次出让方拟转让股份总数为 4,000,000 股，占公司总股本的比例为 3.89%， 占剔除公司已回购股份后的总股本的比例为 3.93% ； 本次询价转让不通过集中竞价交易或大宗交易方式进行，不属于通过二 级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投 资者。 一、 拟参与转让的股东情况 (一) 出让方的名称、持股 ...

Group 1 - The core viewpoint of the news is that Enwei Pharmaceutical (301331) expects a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of between 56.5 million to 66.5 million yuan, representing a year-on-year increase of 50.68% to 77.35% [1] - The company anticipates a net profit of 49 million to 59 million yuan after deducting non-recurring gains and losses, indicating a year-on-year growth of 41.09% to 69.88% [1] - Enwei Pharmaceutical focuses on the research, production, and sales of traditional Chinese medicine, chemical drugs, and health personal care products, with a strong emphasis on gynecological products, pediatric medications, respiratory system drugs, and health personal care items [1] Group 2 - The rapid growth in 2025 is driven by two main factors: steady increase in main business revenue leading to expanded net profit scale, and reduced costs related to the stock incentive plan, which effectively optimized the profit structure [2] - The estimated impact of non-recurring gains and losses on the company's net profit is approximately 7.5 million yuan, providing additional support for the growth in performance [2]

近日，恩威医药披露2025年度业绩预告，预计2025年归母净利润为5650万元至6650万元，同比增长50.68%至77.35%。 2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少。 （恩威医药公告） ...

Core Viewpoint - The company, Enwei Pharmaceutical, anticipates a significant increase in net profit for the year 2025, projecting a rise of over 50% compared to the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is set from January 1, 2025, to December 31, 2025 [1]. - The expected net profit is projected to be positive and to increase by more than 50% [2]. Group 2: Communication with Auditors - The data related to the performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by the accounting firm [2]. - The company has had preliminary discussions with the accounting firm regarding the performance forecast, and there are no significant disagreements [2]. Group 3: Reasons for Performance Change - The primary reason for the anticipated increase in performance for 2025 is attributed to growth in main business revenue, which will lead to an increase in net profit, along with a reduction in the amortization costs of the equity incentive plan [3]. Group 4: Non-Recurring Gains - It is estimated that non-recurring gains and losses will impact net profit by approximately 7.5 million yuan [4]. Group 5: Additional Information - The performance forecast data is preliminary, and detailed financial data will be disclosed in the annual report for 2025 [5].